Syros Pharmaceuticals Stock Price, News & Analysis (NASDAQ:SYRS)

$10.18 +0.13 (+1.29 %)
(As of 02/21/2018 04:00 PM ET)
Previous Close$10.05
Today's Range$10.06 - $10.50
52-Week Range$6.30 - $24.38
Volume162,765 shs
Average Volume298,205 shs
Market Capitalization$324.78 million
P/E RatioN/A
Dividend YieldN/A
Beta-2.36

About Syros Pharmaceuticals (NASDAQ:SYRS)

Syros Pharmaceuticals logoSyros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines. The Company's drug programs include SY-1425 (retinoic acid receptor alpha (RARa) agonist) and SY-1365 (cyclin-dependent kinase 7 (CDK7) inhibitor). SY-1425 (tamibarotene) is an oral, potent and selective agonist, or activator, of the transcription factor RARa. SY-1365 is a small molecule inhibitor of the transcriptional kinase known as CDK7. The Company is using its platform to analyze gene expression programs across additional cancers, inflammatory diseases and other diseases to identify optimal points of therapeutic intervention in specific subsets of patients.

Receive SYRS News and Ratings via Email

Sign-up to receive the latest news and ratings for SYRS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biopharmaceuticals
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SYRS
CUSIPN/A
Phone617-744-1340

Debt

Debt-to-Equity RatioN/A
Current Ratio9.01%
Quick Ratio9.01%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$320,000.00
Price / Sales1,024.04
Cash FlowN/A
Price / CashN/A
Book Value$3.45 per share
Price / Book2.95

Profitability

Trailing EPS($2.01)
Net Income$-47,740,000.00
Net MarginsN/A
Return on Equity-62.01%
Return on Assets-55.65%

Miscellaneous

Employees55
Outstanding Shares32,190,000

Syros Pharmaceuticals (NASDAQ:SYRS) Frequently Asked Questions

What is Syros Pharmaceuticals' stock symbol?

Syros Pharmaceuticals trades on the NASDAQ under the ticker symbol "SYRS."

How were Syros Pharmaceuticals' earnings last quarter?

Syros Pharmaceuticals Inc (NASDAQ:SYRS) announced its quarterly earnings results on Wednesday, November, 8th. The company reported ($0.53) earnings per share (EPS) for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.53). View Syros Pharmaceuticals' Earnings History.

When will Syros Pharmaceuticals make its next earnings announcement?

Syros Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, May, 14th 2018. View Earnings Estimates for Syros Pharmaceuticals.

Where is Syros Pharmaceuticals' stock going? Where will Syros Pharmaceuticals' stock price be in 2018?

8 analysts have issued 1-year price targets for Syros Pharmaceuticals' shares. Their forecasts range from $10.00 to $33.00. On average, they expect Syros Pharmaceuticals' stock price to reach $23.83 in the next year. View Analyst Ratings for Syros Pharmaceuticals.

What are Wall Street analysts saying about Syros Pharmaceuticals stock?

Here are some recent quotes from research analysts about Syros Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Syros Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on treatments for cancer and immune-mediated diseases as well as building a pipeline of gene control medicines. The company's product pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia and relapsed high-risk myelodysplastic syndrome and SY-1365, a selective CDK7 inhibitor for acute leukemia which is in preclinical stage. Syros Pharmaceuticals, Inc. is based in Cambridge, Massachusetts. " (1/20/2018)
  • 2. Cann analysts commented, "Syros announced today that FDA has granted orphan drug designation to SY-1425 for the treatment of acute myeloid leukemia (AML). FDA’s Office of Orphan Drug Products grants orphan status to support development of medicines for the treatment of rare diseases that affect fewer than 200,000 people in the United States. Orphan drug designation may provide certain benefits, including a seven-year period of market exclusivity if the drug is approved, tax credits for qualified clinical trials and an exemption from FDA application fees." (8/21/2017)

Who are some of Syros Pharmaceuticals' key competitors?

Who are Syros Pharmaceuticals' key executives?

Syros Pharmaceuticals' management team includes the folowing people:

  • Peter Wirth, Independent Chairman of the Board (Age 66)
  • Nancy A. Simonian M.D., Principal Financial Officer, Director (Age 56)
  • Kyle D. Kuvalanka, Chief Operating Officer (Age 48)
  • Colleen DeSimone, Principal Accounting Officer (Age 47)
  • Eric R. Olson Ph.D., Chief Scientific Officer (Age 59)
  • Gerald E. Quirk Esq., Chief Legal Officer (Age 49)
  • David A. Roth M.D., Chief Medical Officer (Age 54)
  • Srinivas Akkaraju M.D., Ph.D., Director (Age 49)
  • Stephane Bancel, Independent Director (Age 44)
  • Marsha H. Fanucci, Independent Director (Age 63)

When did Syros Pharmaceuticals IPO?

(SYRS) raised $60 million in an initial public offering on Thursday, June 30th 2016. The company issued 4,000,000 shares at $14.00-$16.00 per share. Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Who owns Syros Pharmaceuticals stock?

Syros Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include ARK Investment Management LLC (2.59%), Candriam Luxembourg S.C.A. (0.67%), Opaleye Management Inc. (0.23%), AWM Investment Company Inc. (0.20%), Deutsche Bank AG (0.09%) and Tower Research Capital LLC TRC (0.07%). Company insiders that own Syros Pharmaceuticals stock include Colleen Elizabeth Desimone, Eric R Olson, Jeremy P Springhorn, Redmile Group, Llc, Richard A Young, Robert Nelsen and Srinivas Akkaraju. View Institutional Ownership Trends for Syros Pharmaceuticals.

Who sold Syros Pharmaceuticals stock? Who is selling Syros Pharmaceuticals stock?

Syros Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including AWM Investment Company Inc., Opaleye Management Inc., Hamilton Lane Advisors LLC and Deutsche Bank AG. Company insiders that have sold Syros Pharmaceuticals company stock in the last year include Colleen Elizabeth Desimone, Eric R Olson and Richard A Young. View Insider Buying and Selling for Syros Pharmaceuticals.

Who bought Syros Pharmaceuticals stock? Who is buying Syros Pharmaceuticals stock?

Syros Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Candriam Luxembourg S.C.A., Virtu Financial LLC, Tower Research Capital LLC TRC, Adalta Capital Management LLC, Two Sigma Advisers LP and Two Sigma Investments LP. Company insiders that have bought Syros Pharmaceuticals stock in the last two years include Jeremy P Springhorn, Redmile Group, Llc, Robert Nelsen and Srinivas Akkaraju. View Insider Buying and Selling for Syros Pharmaceuticals.

How do I buy Syros Pharmaceuticals stock?

Shares of Syros Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Syros Pharmaceuticals' stock price today?

One share of Syros Pharmaceuticals stock can currently be purchased for approximately $10.18.

How big of a company is Syros Pharmaceuticals?

Syros Pharmaceuticals has a market capitalization of $324.78 million and generates $320,000.00 in revenue each year. The company earns $-47,740,000.00 in net income (profit) each year or ($2.01) on an earnings per share basis. Syros Pharmaceuticals employs 55 workers across the globe.

How can I contact Syros Pharmaceuticals?

Syros Pharmaceuticals' mailing address is 620 Memorial Drive Suite300, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-744-1340 or via email at [email protected]


MarketBeat Community Rating for Syros Pharmaceuticals (SYRS)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  140 (Vote Outperform)
Underperform Votes:  110 (Vote Underperform)
Total Votes:  250
MarketBeat's community ratings are surveys of what our community members think about Syros Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Syros Pharmaceuticals (NASDAQ:SYRS) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.752.752.862.71
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $23.83$23.83$26.14$21.77
Price Target Upside: 139.54% upside139.54% upside59.00% upside7.92% upside

Syros Pharmaceuticals (NASDAQ:SYRS) Consensus Price Target History

Price Target History for Syros Pharmaceuticals (NASDAQ:SYRS)

Syros Pharmaceuticals (NASDAQ:SYRS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/8/2018OppenheimerSet Price TargetBuy$28.00HighView Rating Details
12/21/2017HC WainwrightReiterated RatingHold$10.00LowView Rating Details
12/11/2017CowenReiterated RatingBuyHighView Rating Details
10/31/2017Piper Jaffray CompaniesReiterated RatingOverweight -> Overweight$30.00N/AView Rating Details
10/23/2017Roth CapitalInitiated CoverageNeutral -> Neutral$15.00N/AView Rating Details
9/28/2017JMP SecuritiesUpgradeMarket Perform -> Outperform$33.00HighView Rating Details
8/21/2017CannReiterated RatingBuy$28.00LowView Rating Details
8/10/2017WedbushReiterated RatingOutperform$25.00 -> $22.84MediumView Rating Details
(Data available from 2/21/2016 forward)

Earnings

Syros Pharmaceuticals (NASDAQ:SYRS) Earnings History and Estimates Chart

Earnings by Quarter for Syros Pharmaceuticals (NASDAQ:SYRS)

Syros Pharmaceuticals (NASDAQ SYRS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/14/2018N/AView Earnings Details
11/8/2017Q3 2017($0.53)($0.53)ViewN/AView Earnings Details
8/9/2017Q2 2017($0.55)($0.52)ViewN/AView Earnings Details
5/15/2017Q1 2017($0.59)($0.49)$1.10 millionViewN/AView Earnings Details
3/20/2017Q4 2016($0.64)($0.47)$0.32 millionViewN/AView Earnings Details
11/14/2016Q316($0.54)($0.65)ViewN/AView Earnings Details
8/15/2016Q2 2016($0.56)($5.42)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Syros Pharmaceuticals (NASDAQ:SYRS) Earnings Estimates

2018 EPS Consensus Estimate: ($2.41)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.59)($0.16)($0.38)
Q2 20182($0.72)($0.62)($0.67)
Q3 20182($0.74)($0.58)($0.66)
Q4 20182($0.77)($0.64)($0.71)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Syros Pharmaceuticals (NASDAQ:SYRS)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Syros Pharmaceuticals (NASDAQ SYRS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 33.60%
Institutional Ownership Percentage: 48.81%
Insider Trades by Quarter for Syros Pharmaceuticals (NASDAQ:SYRS)
Insider Trades by Quarter for Syros Pharmaceuticals (NASDAQ:SYRS)

Syros Pharmaceuticals (NASDAQ SYRS) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/31/2018Srinivas AkkarajuDirectorBuy209,424$9.55$1,999,999.20View SEC Filing  
12/15/2017Jeremy P SpringhornInsiderBuy15,000$9.08$136,200.00View SEC Filing  
12/14/2017Srinivas AkkarajuDirectorBuy109,774$9.03$991,259.22View SEC Filing  
10/23/2017Colleen Elizabeth DesimoneInsiderSell550$16.06$8,833.00View SEC Filing  
8/14/2017Richard A YoungDirectorSell3,282$22.00$72,204.00420,101View SEC Filing  
8/7/2017Eric R OlsonInsiderSell2,500$23.59$58,975.002,500View SEC Filing  
7/25/2017Eric R OlsonInsiderSell12,500$21.85$273,125.0012,500View SEC Filing  
7/25/2017Richard A YoungDirectorSell3,282$22.09$72,499.38423,383View SEC Filing  
7/6/2016Redmile Group, LlcMajor ShareholderBuy432,746$12.50$5,409,325.00View SEC Filing  
7/6/2016Robert NelsenDirectorBuy400,000$12.50$5,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Syros Pharmaceuticals (NASDAQ SYRS) News Headlines

Source:
DateHeadline
Syros to Present at Leerink Partners 7th Annual Global Healthcare ConferenceSyros to Present at Leerink Partners 7th Annual Global Healthcare Conference
finance.yahoo.com - February 16 at 9:54 AM
Syros Pharmaceuticals (SYRS) and Myovant Sciences (MYOV) Head to Head ContrastSyros Pharmaceuticals (SYRS) and Myovant Sciences (MYOV) Head to Head Contrast
www.americanbankingnews.com - February 15 at 5:10 PM
Syros Pharmaceuticals Inc (SYRS) Expected to Announce Earnings of -$0.57 Per ShareSyros Pharmaceuticals Inc (SYRS) Expected to Announce Earnings of -$0.57 Per Share
www.americanbankingnews.com - February 15 at 8:58 AM
Syros Announces Pricing of $40 Million Public Offering of Common StockSyros Announces Pricing of $40 Million Public Offering of Common Stock
finance.yahoo.com - February 8 at 5:27 AM
Syros Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional SharesSyros Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
finance.yahoo.com - February 8 at 5:27 AM
Syros Pharmaceuticals Inc (SYRS) Given Average Recommendation of "Buy" by AnalystsSyros Pharmaceuticals Inc (SYRS) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - February 2 at 7:42 PM
Syros Pharmaceuticals Inc (SYRS) Director Purchases $1,999,999.20 in StockSyros Pharmaceuticals Inc (SYRS) Director Purchases $1,999,999.20 in Stock
www.americanbankingnews.com - February 2 at 6:16 PM
Syros Pharmaceuticals (SYRS) Prices 4.19M Share Common Offering at $9.55/ShSyros Pharmaceuticals (SYRS) Prices 4.19M Share Common Offering at $9.55/Sh
www.streetinsider.com - February 1 at 5:43 AM
Syros Announces Proposed Offering of Common StockSyros Announces Proposed Offering of Common Stock
finance.yahoo.com - January 31 at 3:17 PM
Syros Pharmaceuticals (SYRS) Announces Proposed $40M Offering of Common StockSyros Pharmaceuticals (SYRS) Announces Proposed $40M Offering of Common Stock
www.streetinsider.com - January 31 at 5:39 AM
-$0.57 EPS Expected for Syros Pharmaceuticals Inc (SYRS) This Quarter-$0.57 EPS Expected for Syros Pharmaceuticals Inc (SYRS) This Quarter
www.americanbankingnews.com - January 29 at 7:50 AM
FY2020 Earnings Forecast for Syros Pharmaceuticals Inc Issued By Oppenheimer (SYRS)FY2020 Earnings Forecast for Syros Pharmaceuticals Inc Issued By Oppenheimer (SYRS)
www.americanbankingnews.com - January 24 at 8:36 PM
Syros Announces Issuance of U.S. Patents Covering Methods for Stratifying Patients for Treatment with SY-1425, Its First-in-Class Selective RARα AgonistSyros Announces Issuance of U.S. Patents Covering Methods for Stratifying Patients for Treatment with SY-1425, Its First-in-Class Selective RARα Agonist
finance.yahoo.com - January 22 at 3:21 PM
Syros Pharmaceuticals (SYRS) Downgraded to "Hold" at Zacks Investment ResearchSyros Pharmaceuticals (SYRS) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - January 20 at 4:08 PM
Zacks: Analysts Anticipate Syros Pharmaceuticals Inc (SYRS) to Post -$0.57 EPSZacks: Analysts Anticipate Syros Pharmaceuticals Inc (SYRS) to Post -$0.57 EPS
www.americanbankingnews.com - January 12 at 9:30 AM
Q1 2018 EPS Estimates for Syros Pharmaceuticals Inc (SYRS) Lifted by OppenheimerQ1 2018 EPS Estimates for Syros Pharmaceuticals Inc (SYRS) Lifted by Oppenheimer
www.americanbankingnews.com - January 11 at 9:36 AM
Q1 2018 Earnings Estimate for Syros Pharmaceuticals Inc Issued By Wedbush (SYRS)Q1 2018 Earnings Estimate for Syros Pharmaceuticals Inc Issued By Wedbush (SYRS)
www.americanbankingnews.com - January 11 at 9:36 AM
Syros Pharmaceuticals Inc (SYRS) Receives Average Recommendation of "Buy" from AnalystsSyros Pharmaceuticals Inc (SYRS) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - January 8 at 5:34 PM
Syros Pharmaceuticals (SYRS) Provides Outline of Strategic Priorities and Expected Milestones for 2018Syros Pharmaceuticals (SYRS) Provides Outline of Strategic Priorities and Expected Milestones for 2018
www.streetinsider.com - January 8 at 4:17 PM
Oppenheimer Analysts Give Syros Pharmaceuticals (SYRS) a $28.00 Price TargetOppenheimer Analysts Give Syros Pharmaceuticals (SYRS) a $28.00 Price Target
www.americanbankingnews.com - January 8 at 11:50 AM
Incyte and Syros Announce Global Target Discovery and Validation Collaboration Focused on Myeloproliferative NeoplasmsIncyte and Syros Announce Global Target Discovery and Validation Collaboration Focused on Myeloproliferative Neoplasms
finance.yahoo.com - January 8 at 9:33 AM
Syros Announces 2018 Strategic Priorities and Expected MilestonesSyros Announces 2018 Strategic Priorities and Expected Milestones
finance.yahoo.com - January 8 at 9:33 AM
Financial Comparison: Auxilium Pharmaceuticals (AUXL) and Syros Pharmaceuticals (SYRS)Financial Comparison: Auxilium Pharmaceuticals (AUXL) and Syros Pharmaceuticals (SYRS)
www.americanbankingnews.com - January 7 at 5:06 AM
Syros Pharmaceuticals (SYRS) Upgraded at Zacks Investment ResearchSyros Pharmaceuticals (SYRS) Upgraded at Zacks Investment Research
www.americanbankingnews.com - January 5 at 11:36 AM
Syros to Present at 36th Annual J.P. Morgan Healthcare ConferenceSyros to Present at 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 4 at 10:42 AM
Syros Announces Clinical Supply Agreement with Janssen to Evaluate SY-1425, Its First-in-Class Selective RARα Agonist, in Combination with Daratumumab in Genomically Defined AML and MDS PatientsSyros Announces Clinical Supply Agreement with Janssen to Evaluate SY-1425, Its First-in-Class Selective RARα Agonist, in Combination with Daratumumab in Genomically Defined AML and MDS Patients
finance.yahoo.com - January 2 at 10:36 AM
Short Interest in Syros Pharmaceuticals Inc (SYRS) Rises By 78.7%Short Interest in Syros Pharmaceuticals Inc (SYRS) Rises By 78.7%
www.americanbankingnews.com - December 31 at 3:50 AM
Peregrine Pharmaceuticals (PPHM) versus Syros Pharmaceuticals (SYRS) Head to Head AnalysisPeregrine Pharmaceuticals (PPHM) versus Syros Pharmaceuticals (SYRS) Head to Head Analysis
www.americanbankingnews.com - December 26 at 5:48 AM
HC Wainwright Reiterates "Hold" Rating for Syros Pharmaceuticals (SYRS)HC Wainwright Reiterates "Hold" Rating for Syros Pharmaceuticals (SYRS)
www.americanbankingnews.com - December 21 at 1:42 PM
Insider Buying: Syros Pharmaceuticals Inc (SYRS) Insider Purchases 15,000 Shares of StockInsider Buying: Syros Pharmaceuticals Inc (SYRS) Insider Purchases 15,000 Shares of Stock
www.americanbankingnews.com - December 15 at 9:22 PM
Syros Pharmaceuticals Inc (SYRS) Director Srinivas Akkaraju Acquires 109,774 SharesSyros Pharmaceuticals Inc (SYRS) Director Srinivas Akkaraju Acquires 109,774 Shares
www.americanbankingnews.com - December 15 at 4:14 AM
Syros Pharmaceuticals Inc (SYRS) Receives Consensus Rating of "Buy" from AnalystsSyros Pharmaceuticals Inc (SYRS) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - December 14 at 9:28 PM
Wedbush Equities Analysts Lower Earnings Estimates for Syros Pharmaceuticals Inc (SYRS)Wedbush Equities Analysts Lower Earnings Estimates for Syros Pharmaceuticals Inc (SYRS)
www.americanbankingnews.com - December 14 at 6:50 AM
Syros Pharmaceuticals (SYRS) in Focus: Stock Moves 12.7% HigherSyros Pharmaceuticals (SYRS) in Focus: Stock Moves 12.7% Higher
finance.yahoo.com - December 13 at 11:10 AM
Syros Pharmaceuticals Plummets in Premarket Trading MondaySyros Pharmaceuticals Plummets in Premarket Trading Monday
finance.yahoo.com - December 12 at 11:17 AM
Syros Pharmaceuticals (SYRS) Earns Buy Rating from CowenSyros Pharmaceuticals (SYRS) Earns Buy Rating from Cowen
www.americanbankingnews.com - December 12 at 12:22 AM
Mid-Afternoon Market Update: NASDAQ Up 0.5%; bluebird bio Shares Spike HigherMid-Afternoon Market Update: NASDAQ Up 0.5%; bluebird bio Shares Spike Higher
www.nasdaq.com - December 11 at 4:18 PM
5 Keys To Understanding Syros Pharmas ASH Presentation5 Keys To Understanding Syros Pharma's ASH Presentation
www.msn.com - December 11 at 4:18 PM
Goldcorp, Spark Therapeutics Tumble into Monday’s 52-Week Low ClubGoldcorp, Spark Therapeutics Tumble into Monday’s 52-Week Low Club
247wallst.com - December 11 at 4:18 PM
Should You Be Content With Syros Pharmaceuticals Inc’s (SYRS) 71.5% Earnings Growth?Should You Be Content With Syros Pharmaceuticals Inc’s (SYRS) 71.5% Earnings Growth?
finance.yahoo.com - December 11 at 11:29 AM
Syros Announces New Preclinical Data on SY-1365, Its First-in-Class Selective CDK7 Inhibitor, Pointing to a Potential Biomarker of Response and Combination ApproachSyros Announces New Preclinical Data on SY-1365, Its First-in-Class Selective CDK7 Inhibitor, Pointing to a Potential Biomarker of Response and Combination Approach
finance.yahoo.com - December 10 at 10:35 AM
Syros Announces Initial Clinical Data from Ongoing Phase 2 Trial of SY-1425 Showing Biological and Clinical Activity as Single Agent in Genomically Defined AML and MDS PatientsSyros Announces Initial Clinical Data from Ongoing Phase 2 Trial of SY-1425 Showing Biological and Clinical Activity as Single Agent in Genomically Defined AML and MDS Patients
finance.yahoo.com - December 10 at 10:35 AM
Zacks: Brokerages Anticipate Syros Pharmaceuticals, Inc. (SYRS) to Announce -$0.55 EPSZacks: Brokerages Anticipate Syros Pharmaceuticals, Inc. (SYRS) to Announce -$0.55 EPS
www.americanbankingnews.com - December 9 at 5:30 AM
Oppenheimer Reiterates Buy Rating for Syros Pharmaceuticals (SYRS)Oppenheimer Reiterates Buy Rating for Syros Pharmaceuticals (SYRS)
www.americanbankingnews.com - December 8 at 3:20 PM
Syros Presents New Preclinical Data on SY-1365, Its First-in-Class Selective CDK7 Inhibitor, and Discovery of Potential New Drug Targets in Triple Negative Breast Cancer at San Antonio Breast Cancer SymposiumSyros Presents New Preclinical Data on SY-1365, Its First-in-Class Selective CDK7 Inhibitor, and Discovery of Potential New Drug Targets in Triple Negative Breast Cancer at San Antonio Breast Cancer Symposium
finance.yahoo.com - December 7 at 11:13 AM
BioMarin Pharmaceutical (BMRN) vs. Syros Pharmaceuticals (SYRS) Head-To-Head SurveyBioMarin Pharmaceutical (BMRN) vs. Syros Pharmaceuticals (SYRS) Head-To-Head Survey
www.americanbankingnews.com - December 5 at 3:30 PM
Syros Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SYRS-US : December 1, 2017Syros Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SYRS-US : December 1, 2017
finance.yahoo.com - December 1 at 6:01 PM
Blog Exposure - Exelixis Announces Phase-3 CELESTIAL Trial Results of Cabozantinib in Previously Treated Advanced Hepatocellular CarcinomaBlog Exposure - Exelixis Announces Phase-3 CELESTIAL Trial Results of Cabozantinib in Previously Treated Advanced Hepatocellular Carcinoma
finance.yahoo.com - November 27 at 4:05 PM
Syros Pharmaceuticals, Inc. (SYRS) Given Average Rating of "Buy" by BrokeragesSyros Pharmaceuticals, Inc. (SYRS) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - November 19 at 5:32 PM
Critical Analysis: Syros Pharmaceuticals (SYRS) vs. Kadmon Holdings (KDMN)Critical Analysis: Syros Pharmaceuticals (SYRS) vs. Kadmon Holdings (KDMN)
www.americanbankingnews.com - November 15 at 5:46 PM

SEC Filings

Syros Pharmaceuticals (NASDAQ:SYRS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Syros Pharmaceuticals (NASDAQ SYRS) Stock Chart for Wednesday, February, 21, 2018

Loading chart…

This page was last updated on 2/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.